Related Experiment Video

Updated: Jun 25, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Glioma angiogenesis: Towards novel RNA therapeutics

Thomas Würdinger1, Bakhos A Tannous

  • 1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA. twurdinger@mgh.harvard.edu

Cell Adhesion & Migration
|March 6, 2009
PubMed

Insights

Brain tumor blood vessel growth (angiogenesis) is a treatment target. RNA-based therapies, like angiomirs, offer a promising "one-hit multiple-target" approach for brain tumor anti-angiogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Brain tumors feature abnormal blood vessel formation (angiogenesis), crucial for tumor growth and nutrient supply.
  • Current anti-angiogenesis therapies targeting single proteins show limited efficacy.
  • RNA-based therapeutics, including small-interfering RNAs (siRNAs), are emerging as novel anti-angiogenesis strategies.

Purpose of the Study:

  • To review emerging anti-angiogenesis technologies.
  • To emphasize the potential of RNA-based therapeutics in combating brain tumor angiogenesis.

Main Methods:

  • Discussion of current angiogenesis inhibitors and their limitations.
  • Exploration of RNA interference (RNAi) mechanisms, including siRNAs.
  • Introduction to angiomirs (angiogenesis-related microRNAs) as a novel therapeutic class.

Main Results:

  • Angiomirs offer a "one-hit multiple-target" therapeutic advantage over single-target inhibitors.
  • RNA-based inhibitors demonstrate potential for silencing multiple angiogenic targets simultaneously.
  • Emerging RNA therapeutics show promise for more effective brain tumor anti-angiogenesis.

Conclusions:

  • RNA-based therapeutics, particularly angiomirs, represent a significant advancement in anti-angiogenesis strategies.
  • Targeting multiple angiogenic pathways with RNA molecules could overcome limitations of current treatments.
  • Further research into RNA-based therapies holds promise for improved brain tumor treatment outcomes.

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...